Enriched Monocyte-Derived Dendritic Cell Vaccine Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and radiation, fail to induce durable tumor-specific responses, and dendritic cell vaccination methods require improvement in antigen presenting cell efficacy to enhance immune-based therapies.
Innovation Solution
The use of monocytes enriched for non-classical and intermediate monocytes, promoted by cytokines like macrophage colony-stimulating factor, TGF-β1, and MCP-1, to differentiate into dendritic cells with increased costimulatory molecule expression, improving their efficacy in immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dendritic cell vaccination methods are used, then the treatment can be administered, but the antigen presenting cell efficacy is insufficient to generate durable tumor-specific responses
Solution Approach 1:
The patent applies local quality by selecting and enriching for specific subsets of monocytes (non-classical and intermediate monocytes) rather than using the general monocyte population. This selective enrichment creates a heterogeneous DC product with superior quality characteristics, specifically enhanced costimulatory molecule expression and improved T cell activation capacity, thereby resolving the contradiction between reliability of tumor-specific response and productivity of antigen presenting cell efficacy
Solution Approach 2:
The patent employs parameter changes by modifying the differentiation conditions through specific cytokine combinations (GM-CSF, IL-4, TNF-α, prostaglandin E2) and culture protocols to generate dendritic cells with altered functional parameters. These parameter changes result in DCs with enhanced costimulatory molecule expression and improved ability to activate T cells, thus improving both the reliability of durable responses and the productivity of antigen presenting cell efficacy
2Ease of manufacture
If dendritic cells are differentiated from standard monocyte populations, then the production process is straightforward, but the costimulatory molecule expression is insufficient for optimal T cell activation
Solution Approach 1:
The patent applies preliminary action by pre-enriching the monocyte population for non-classical and intermediate monocytes before initiating dendritic cell differentiation. This preliminary enrichment step ensures that the starting material has the desired characteristics for producing high-quality DCs with enhanced costimulatory molecule expression, while maintaining a relatively simple overall manufacturing process
Solution Approach 2:
The patent uses composite materials by combining multiple cytokines (GM-CSF, IL-4, TNF-α, prostaglandin E2) in a specific differentiation cocktail to generate dendritic cells with composite functional properties. This composite approach creates DCs that simultaneously exhibit enhanced costimulatory molecule expression, improved T cell activation capacity, and maintained ease of manufacture through a standardized protocol
Data Source
AI summary
Compositions and methods are provided for converting the predominant circulating classical monocytes to a non-classical and/or intermediate monocyte phenotype through cytokine stimulation via, for example, macrophage colony-stimulating factor. Once cultured into dendritic cells, these non-classical and/or intermediate monocyte derived cells have increased costimulatory molecule expression, which leads to improved immune and clinical responses in cancer patients receiving dendritic cell vaccination and other immunotherapies. In addition, assays and diagnostic and theranostic methods are provided herein that relate to the discoveries that, prior to treatment, intermediate (CD14+CD16+) and non-classical (CD14dimCD16+) monocytes are increased more than two-fold in patients who later had complete responses to dendritic cell therapy or DC vaccination.